gp100:280-288(288V) peptide vaccine

A therapeutic cancer vaccine composed of a synthetic peptide corresponding to amino acids 280 through 288 of the melanoma-associated antigen glycoprotein 100 (gp100), with a valine substitution at position 288 (hence "288V") to enhance immunogenicity. The vaccine is designed to stimulate an immune response, particularly cytotoxic T lymphocyte (CTL) responses, against melanoma cells expressing the gp100 antigen. It is typically administered in patients with high-risk or advanced melanoma and has been evaluated in early-phase clinical trials for its safety and ability to induce immune responses. The primary developer is the National Cancer Institute, and it has also been studied by Bristol Myers Squibb[1][2][4][5].

Other names

gp100 280–288 peptide vaccineHLA-A2-restricted peptide YLEPGPVTAHLA-A-2-restricted peptide YLEPGPVTAHLA-A 2-restricted peptide YLEPGPVTAmodified gp100 melanoma antigen peptide vaccine